首页> 外文期刊>Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association >Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
【24h】

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

机译:单独的HERS2阳性晚期胃癌患者TRASTUZUMAB加S-1的多中心期II研究(Jaccro GC-06)

获取原文
获取原文并翻译 | 示例
           

摘要

Background S-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. In the HERBIS-1 trial, trastuzumab combined with S-1 plus cisplatin showed promising antitumor activity in patients with HER2-positive AGC. However, cisplatin has several important drawbacks, including vomiting and renal toxicity. These disadvantages of cisplatin are prominent in elderly patients. Therefore, we conducted a prospective phase II study of trastuzumab plus S-1 without cisplatin in elderly patients with HER2-positive AGC.
机译:背景技术S-1加顺铂是亚洲晚期胃癌(AGC)的标准方案。 Toga试验建立了氟嘧啶加顺铂和曲妥珠单抗,作为人表皮生长因子受体2(HER2) - 阳性AGC的标准处理。 在Herbis-1试验中,曲妥珠单抗与S-1加顺铂相结合,患有HER2阳性AGC患者的有前途的抗肿瘤活性。 然而,顺铂有几个重要的缺点,包括呕吐和肾毒性。 顺铂的这些缺点在老年患者中都很突出。 因此,我们进行了一项前瞻性期II研究,对RASTUZUMAB加S-1的研究,没有顺铂的老年患者2阳性AGC患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号